MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has introduced the ADRENALIN® ready-to-use premixed intravenous (IV) bag, the first FDA-approved epinephrine premixed bag prepared directly by the manufacturer. This significant development is poised to streamline hospital workflows and enhance patient care by reducing time, effort, and the potential for medication errors.
The ADRENALIN® bag is part of Endo Injectable Solutions’ TruDelivery® product line, offering healthcare providers a more efficient solution for administering epinephrine in critical care settings. Unlike traditional methods requiring preparation or transfer, the premixed bag eliminates these steps, reducing waste and costs while improving accuracy and convenience.
The product’s 24-month shelf life at room temperature and single-port IV tubing minimize risks associated with medication errors. This latest addition complements Endo’s existing range, which includes epinephrine in single-dose and multi-dose vials.
Scott Sims, Senior Vice President and General Manager of Endo Injectable Solutions & Generics, praised the launch, stating, “The first-ever ready-to-use epinephrine premixed bag represents an advancement for both providers and patients thanks to a delivery system that provides greater workflow efficiency, saves time, and reduces the risk of medication error.”
ADRENALIN® is indicated for the treatment of hypotension associated with septic shock, providing a critical tool for healthcare providers while highlighting Endo’s efforts to support quality patient care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.